The transaction is set to be completed in the fourth quarter of 2019.
Mallinckrodt Pharamceuticals, a UK biopharmaceutical company, announced on Sept. 10, 2019 that it has entered into an agreement to sell BioVectra Inc., its contract manufacturing and development organization (CDMO) business and a wholly owned subsidiary, to H.I.G Capital, a private equity firm based in Miami, FL, for $250 million.
The agreement enables Mallinckrodt to capture future BioVectra growth potential through a fixed consideration of $175 million, consisting of an upfront payment of $135 million, a long-term note for $40 million, and contingent payments of up to $75 million. BioVectra will remain an active pharmaceutical ingredient supplier for Mallinckrodt's specialty brands business under a long-term arrangement.
"While we recognize the longer-term growth potential for BioVectra, we believe that the structure of this deal enables us to participate in the future success of the business, and therefore we see this sale as the best option for both Mallinckrodt and BioVectra moving forward," said Mark Trudeau, president and CEO of Mallinckrodt, in a company press release.
"We are excited to support BioVectra's exceptional leadership and highly dedicated employees," added Mike Gallagher, managing director at H.I.G. Capital, in the press release. "BioVectra demonstrates a tremendous ability to generate robust organic growth and utilizes a broad set of technical capabilities to deliver outstanding service and quality. They are completing major capital expenditure programs to significantly expand capacity, and the company is well positioned to capitalize on growing demand for their services."
The transaction is set to be completed in the fourth quarter of 2019 and will include all of BioVectra's sites in Prince Edward Island, Nova Scotia, Canada, as well as its employee base.
Source: Mallinckrodt
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.